tbuckley/cabot-search huggingface dataset:
Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.
Authors: Giordano Fabricio Cittolin Santos, Malshundria Prophet, Theodore Stewart Gourdin, Leylah Drusbosky, Elisa Marie Ledet, A. Oliver Sartor, Guru Sonpavde, Michael B. Lilly
Journal: Journal of Clinical Oncology (2020)

e17597 Background: Circulating tumor DNA (ctDNA) can be used to identify mutations and amplifications in patients with prostate cancer (PC). Identification of actionable mutations in BRAF may allow the use of targeted therapeutics not typically used in prostate cancer. Methods: We analyzed a ctDNA-based genomic profile database (Guardant Health) with 2274 unique advanced-stage patients, and a tissue-based genomic database (TCGA) with 3178 unique patients (73% locoregional, 27% metastatic). We compared the frequency and types of BRAF anomalies found in those datasets. We calculated the odds ratio of observing other genetic anomalies based on the BRAF mutation and amplification status. Finally, we utilized Principal Component Analysis (PCA) to study the utility of BRAF as a discriminator in identifying genetic subtypes of PC. Results: BRAF missense mutations in PC were found in 3.34% of the 2274 patients in the ctDNA cohort and in 1.1% of the 3178 patients in the TCGA cohort. Variants of Uncertain Significance (VUS) mutations were more commonly identified by ctDNA (53.8% of all mutations) vs TCGA (16.1% of all mutations). Biologically-significant mutations of all classes (I, II, III) were found in both datasets. BRAF mutations were mainly non-V600E and most mutations were clonal. Significant mutations common to both the ctDNA and TCGA cohorts include K601E, G469A, D594G, V600E, G466E, G446R, Q257K, I300V and R271H. Mutations unique to either ctDNA or TCGA datasets were found as well. BRAF mutations are highly associated with additional mutations in CDKN2A, TERT, and KRAS, as well as amplifications of CCNE1, KRAS, CDK6 (p &lt; 0.01). BRAF amplifications are highly associated with multiple other gene amplifications, and with AR mutations (p &lt; 0.01). Tumors with BRAF mutations and with BRAF amplifications are genetically distinct, and PCA indicates that BRAF status accounts for a significant amount of the difference. We described two patients that were treated with MEK targeted therapy with treatment response. Conclusions: 1. The use of ctDNA-based genomic analysis identified BRAF anomalies with a higher frequency than tissue-based techniques, but this is mostly due to higher numbers of VUS mutants found with ctDNA. Biologically significant BRAF mutations are mostly clonal and non-V600E mutations. 2. BRAF mutations and amplifications are associated with other specific gene anomalies. 3. ctDNA is a useful tool for identifying the genomic profile of PC in the clinical setting. 4. PC subjects with BRAF mutations identified by ctDNA may respond to MEK inhibitor therapy.
Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and advice)—An eHealth intervention during chemotherapy.
Authors: Galina Velikova, Kate Absolom, Lorraine Warrington, Carolyn Morris, Eleanor Hudson, Robert Carter, Andrea Gibson, Marie Holmes, Patricia Holch, Claire Hulme, Julia Brown
Journal: Journal of Clinical Oncology (2020)

7002 Background: Routine monitoring of patients’ symptoms can improve symptom management, quality of life (QOL) and survival. eRAPID is an online system for patients to report symptoms, uniquely providing automated severity-dependent advice (self-management or alerts for hospital contact). We evaluated eRAPID impact on patient experiences &amp; clinical care. Methods: A prospective randomized two-arm parallel group trial (1:1 allocation Usual Care (UC): UC+eRAPID). Eligible patients started chemotherapy for colorectal, breast &amp; gynecological cancers at Leeds Cancer Centre. In eRAPID arm, patients completed weekly online symptoms for 18 weeks. Primary outcome: QOL/symptom control (FACT-PWB Physical Wellbeing Scale) at 18 weeks. Secondary outcomes: process of care (admissions/ chemotherapy delivery), patient self-efficacy (Lorig Self-Efficacy Scale) &amp; global QOL (EQ5D).Mixed effects repeated measures models were employed. Results: During Jan 2015-June 2018, we screened 1484 patients; 508/690 eligible patients (73.6%) consented &amp; were randomized (256 eRAPID:252 UC). No statistically significant effect of eRAPID on FACT-PWB score was found at 18 weeks (difference in means 0.20 95% CI -0.81, 1.20; p = 0.699). There was a positive impactat 6 &amp; 12 weeks (1.08, 95% CI 0.12, 2.05; p = 0.028 &amp; 1.01, 95% CI 0.05, 1.98; p = 0.039).In responder analysis lower proportion of eRAPID patients had clinically meaningful deterioration 47.5% at 12 weeks vs 56.3% UC. Pre-planned subgroup analysis found no effect in metastatic disease, but better FACT-PWB in non-metastatic/adjuvant group at 6 &amp; 12 weeks (1.45, 95% CI 0.32, 2.58; p = 0.011 &amp; 1.13; 95% CI 0.07, 2.19; p = 0.036). eRAPID patients reported better self-efficacy (p = 0.007) &amp; QOL EQ5D-VAS at 12 (p = 0.030) &amp; 18 weeks (p = 0.010). There were no differences for admissions/chemotherapy delivery. 3314 online reports were completed, median per patient 14.0 (range 0-117). Emergency alerts were activated in 29/3314 cases (0.9%), self-management advice 2714/3314 (81.9%). Post-hoc analysesshowed high patient adherence was associated with clinicians’ use of the data, high baseline FACT-PWB &amp; older age. High adherence patients had better FACT-PWB scores at 12 weeks. Conclusions: Online symptom monitoring with immediate advice improved symptom control early during adjuvant chemotherapy (6 &amp;12 weeks), helping patient education &amp; self-efficacy. The results support its utility as an improved model for patient care during adjuvant chemotherapy. Clinical trial information: ISRCTN88520246 .
Comparison of three types of intrauterine device inserted immediately after artificial abortion: a multicentral randomized controlled trial
Authors: Yingmei Zhao, Haiyan Dai, Binlie Yang, Jihong Lu
Journal: BMJ (2015)

Objective
To compare the safety and effectiveness of three types of intrauterine device (IUD) inserted immediately after artificial abortion.


Methods
A randomized controlled clinical trial was performed in 4 family planning service stations in Pudong New Area from January to December 2012. Total 1 200 eligible women were randomly assigned to receive three types of IUD: MYCu, TCu380A or G-Cu200 (n=400 in each group) immediately after vacuum aspiration. All subjects were followed up for 12 months. The cumulative rates of termination of three IUD after 12 months were analyzed with WHO LTA 2.0 life table.


Results
Total 1 199 subjects were followed up for 12 months with a drop-out rate of 0.08% (1/1 200). No any uterine perforation was found. During the 12 months the pregnancy rates with IUD in situ in MYCu, TCu380A and G-Cu200 groups were 0.26/100 women year, 0 and 0.52/100 women year, respectively (χ2=1.951, P≥0.2). The rates of expulsion in three groups were 0.26/100 women year, 1.84/100 women year and 2.05/100 women year, respectively(χ2=5.539, P=0.066). The remove rates related to bleeding and paining in three groups were 1.26/100 women year, 7.29/100 women year and 2.76/100 women year, respectively (χ2=21.625, P=0.001). The discontinuation rates related to IUD use in there groups were 3.25/100 women year, 9.00/100 women year and 5.50/100 women year, respectively(χ2=12.191, P=0.004). The rates of Abnormal position in three groups were 1.51/100 women year, 0 and 0.26/100 women year, respectively (χ2=8.649, P=0.014).


Conclusion
Three IUDs inserted immediately after vacuum aspiration are all effective. Among three IUDs, MYCu shows lower expulsion rate, lower discontinuation rate related to IUD use and higher continuous rate; but the abnormal position rate of MYCu is higher than other two types IUD.


Key words: 
Intrauterine devices, copper; Randomized controlled trial; Abortion, induced
搞好家庭长程氧疗改善慢性阻塞性肺疾病患者生存质量
Authors: 何权瀛
Journal: BMJ (2004)

慢性阻塞性肺病(COPD)患者由于通气功能障碍与通气/血流比例失调和肺弥散功能降低,即使在临床缓解期,也往往伴有不同程度的低氧血症,从而导致肺动脉压升高,长此下去容易发生慢性肺源性心脏病和右心衰竭.对于此类患者进行长程家庭氧疗,可以提高患者动脉血氧分压(PaO2),增加组织氧供,缓解缺氧性肺动脉痉挛和红细胞增多,减轻水钠潴留,降低肺动脉压和血液的黏稠度,改善心、脑、肾、肺等重要脏器功能,改善呼吸困难,改善睡眠和生活质量,增强患者运动耐力和生活自理能力,减缓肺源性心脏病的发生,从而减少失代偿性呼吸衰竭的发生次数,减少住院次数、时间和医疗费用.国外循证医学研究结果显示,在所有的干预措施中只有戒烟和家庭长程氧疗这两项措施可以改善COPD患者的预后。
养老机构慢性病管理模式的探讨
Authors: 黄永梅
Journal: BMJ (2007)

由医务人员、养老护理员、娱乐员三方共同参与,对养老机构367位老人做全面健康管理.使老人对高血压、糖尿病的相关知识知晓率明显提高;对164例高血压病者管理率达到100%,高血压控制率由入住时48.8%提高至93.9%,38例糖尿病者92.1%血糖控制在正常.提示养老机构慢性病由医务人员、养老护理员、娱乐员共同参与的管理模式,切实有效,值得推广。
Review of annual compliance of low-dose CT for lung cancer screening among internal medicine resident physicians in a university teaching program.
Authors: Nerea Lopetegui-Lia, Dimitrios Drekolias, Syed Imran Mustafa Jafri, James Vredenburgh
Journal: Journal of Clinical Oncology (2020)

e19187 Background: Lung cancer remains the leading cause of morbidity and mortality, with an estimated 2.1 million newly diagnosed cases each year. A large percentage of cases are detected at an advanced stage, making treatment recalcitrant. Only about 15% are diagnosed at an early stage, highlighting the significance of timely screening. USPSTF recommends annual screening with low-dose computed tomography (LDCT) in adults aged 55-80, who have a 30 pack-year smoking history and are current smokers, or former smokers who have quit within the last 15 years. The National Comprehensive Cancer Network (NCCN) guidelines, as well as the National Lung Screening Trial (NLST), recommend annual screening with LDCT until a person is no longer a candidate for definitive treatment. This study aimed to evaluate the compliance with annual LDCT based on USPSTF guidelines among internal medicine residents from the University of Connecticut residency program at a Clinic in Hartford, Connecticut, USA. Methods: Patients who were under the care of internal medicine residents and who had undergone an initial LDCT for lung cancer screening were included. A total of 61 medical charts were reviewed. Three patients were diagnosed with lung cancer and nineteen patients had their initial LDCT in 2019, and therefore excluded. Results: Out of the 39 patients, 10 patients (25.64%) had a follow-up annual LDCT performed, 2 patients before the annual mark due to various clinical concerns, and 9 patients (23%) in the following 24-48 months. 6 patients (15.38%) had a repeat LDCT ordered but was not done or it was canceled. 12 patients (30.77%) had no repeat LDCT ordered at 12 months. Overall, 69.23% had no follow-up CT at 12 months, and 46.15% with no follow up CT at all at the time of chart review. Conclusions: Based on our analysis, follow-up annual LDCT scans for lung cancer screening on patients under the care of residents-in-training are not being ordered frequently enough. The failure to order annual LDCT could be due to a false sense of relief with a normal initial LDCT, the lack of provider’s awareness of USPSTF guidelines, or insurance issues. Educating primary care providers on the importance of follow-up annual LDCT will ensure early detection and decrease mortality from lung cancer in high risk patient population.
Real-world clinical and economic burden associated with hospitalization in metastatic triple-negative (ER-/PR-/HER2-) breast cancer.
Authors: Amie Tan, Xu Han, Aimee Near, Jenny Tse, Luciana Preger
Journal: Journal of Clinical Oncology (2020)

e19236 Background: Metastatic triple-negative breast cancer (mTNBC) is associated with poorer disease prognosis and higher healthcare utilization and costs compared with other breast cancer subtypes, with hospitalizations being a major cost driver. This study aimed to understand reasons for hospitalization and describe the clinical and economic burden associated with hospitalizations in mTNBC patients following 1L treatment initiation. Methods: mTNBC patients were identified in the IQVIA Real-World Data Adjudicated Claims-US database (Jan. 2012 – Jan. 2019) and indexed on the day of 1L treatment initiation. Women ≥18 years of age with mTNBC who had continuous enrollment for ≥12 months before (baseline) and ≥30 days after (follow-up) index and no evidence of other primary cancers during baseline were included. Patient baseline characteristics and all-cause hospitalizations during follow-up were described. Results: 4,617 mTNBC patients were identified (mean age 54 years; 99.7% with chemotherapy as IL); 1,595 (35%) had ≥ 1 hospitalization during follow-up (mean duration 17 months). More hospitalized patients had ≥2 metastasis sites (25% vs. 15%, p &lt; 0.01) as well as visceral (15% vs. 7%, p &lt; 0.01) or bone metastases (15% vs. 8%, p &lt; 0.01) than non-hospitalized patients. The average time from index to first hospitalization was 7.4 months and hospitalized patients had a mean of 2.4 hospitalizations per patient per year (PPPY), with mean length of stay of 6 days. 25% of hospitalized patients were admitted from the ED. Reasons for hospitalization included chemotherapy-related adverse events (AEs; 76%), followed by disease progression (72%), breast-related surgeries (6%), and others (4%). Common chemotherapy-related AEs included infection or pyrexia (46%), anemia (35%), and neutropenia (17%). Total cost associated with hospitalization was $57,115 PPPY, with the annual out-of-pocket cost averaging $3,659 per patient; mean out-of-pocket cost per hospitalization was $1,840. The proportion of patients with hospitalization was similar between metropolitan and rural patients (35% vs. 37%, p = 0.51), yet metropolitan patients had slightly longer hospital stays (mean 6 vs. 5 days, p = 0.03). Conclusions: Approximately one-third of mTNBC patients were hospitalized following 1L treatment initiation and in turn, bear a high economic burden. New therapies are needed to mitigate the clinical and economic burden associated with hospitalizations in this population.
颅外动脉夹层导致缺血性脑卒中五例分析
Authors: 杨姗杉, 夏圣梅, 卢岩
Journal: BMJ (2011)

动脉夹层是由于动脉内膜破损,血流从血管内皮破裂处流入内膜与中膜之间或中膜与外膜之间所致的血管性病变,前者常见,可导致血管狭窄,后者导致夹层动脉瘤[1].脑供血动脉夹层包括颈动脉系统夹层(ICAD)和椎基底动脉系统夹层(VAD),是继动脉粥样硬化后常见的缺血性脑卒中病因之一[2],临床工作中易被忽视.现回顾性分析首都医科大学宣武医院收治的脑颅外动脉夹层病例的临床与影像特征,以提高对该病的认识. 关键词：动脉瘤;夹层
Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.
Authors: Umut Disel, Fatih Kose, Ahmet Bilici, Mustafa Özgüroğlu, Sezer Saglam, Mesut Seker, Sercan Aksoy, Ibrahim Tek, Yesim Eralp, Nil Molinas Mandel, Gokhan Demir, Cagatay Arslan, Mutlu Demiray, Taflan Salepci, Mehmet Akif Ozturk, Fatih Selcukbiricik, Gokce Temizas, Ebru Gul Fidan
Journal: Journal of Clinical Oncology (2020)

e13646 Background: Most of the frequent cancers present a large number of very rare targetable genomic alterations. Moreover, some oncogenic drivers are shared across several diseases, and their targeting could improve outcome. We think that testing a large number of genes across all tumor types could improve outcomes in patients with “hard-to-treat” advanced cancers. The most important factor for the cancer patient to benefit from precision medicine therapy is the detection of the targeted driver mutations. The objective of this study is to determine clinical advantages of hybrid capture based comprehensive genomic profiling over classical diagnostic methods in the treatment strategies of patients with advanced stage diverse solid tumors in Turkey. Methods: This study was designed as a national, multicenter, descriptive, non-drug, retrospective cohort study. Study data were collected from medical files of patients. Besides, a survey was conducted to investigate the impact of CGP results on the treatment decisions of the clinicians. Results: The study included the data of 118 patients (55; %46.6 female, 63; %53.4 male). The mean period between the diagnosis and CGP analysis was 748 days. For either due to progression (97; 75.2%) or intolerance to therapy (12; 9.3%), the treatment of some cases was discontinued after CGP analysis. The results of the electronic survey for the clinicians indicated that the 57;48.3% of the clinicians change their treatment approach based on the results of the CGP analysis, of these 24; 42.1% preferred on-label treatments,3; 5.3% clinical trials and the 30; 52.6% preferred off-label treatments. 59;69.8% of the clinicians declared that their patients can reach to the revised treatment. 48;42.1% of the clinicians expressed that CGP support was very important in the last treatment decision. This is the interim descriptive statistics of the study. Conclusions: This is the preliminary results of the study. Conclusions will be done after the final analysis of the study
呼吸道异物误诊、漏诊16例分析
Authors: 侯梅荣, 邵新娜, 徐莉
Journal: BMJ (2008)

呼吸道异物是小儿常见的突发急症,也是儿童意外死亡的常见原因之一.一般根据病史及相应查体、辅助检查均能确诊,但少数病例仍由于医师主观、客观原因而造成误诊误治.我科.1996年1月至2006年4月收治16例呼吸道异物误诊病例,其中外院误诊11例,本院误诊5例。
A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.
Authors: Yong Fang, Hongming Pan, Shun Lu, Hong Hu, Qin Lu
Journal: Journal of Clinical Oncology (2020)

e21705 Background: TQ-B3101 is a novel compound, which deacetylated metabolite targets to receptor tyrosine kinases including ALK, ROS1 and MET. Preclinical studies showed TQ-B3101 had a better Inhibition activity and duration compared with equimolar crizotinib. Methods: Patients (pts) with advanced solid tumor failed to standard therapy were enrolled into dose escalation and expansion cohorts. TQ-B3101 was orally administered at doses of 100~300mg QD or 200~350mg BID in a 28-day cycle, then received the same dose until disease progression or intolerable toxicity. Dose escalation was based on dose-limiting toxicities (DLTs) in the first cycle and used “3+3” design to get the maximal tolerated dose (MTD) or recommended phase II dose (RP2D). Other objectives included safety and pharmacokinetics (PK) for all pts, and objective response rate (ORR) for ALK + , ROS1 + and MET amplification pts. Results: As of 20 Dec 2019, 30 pts (median age 51.3, males: 16, females: 14, ALK + : 19, ROS1 + : 6, MET amplification: 2, lung cancer: 27, asymptomatic brain metastasis: 8, ECOG PS 1: 30) were enrolled into 7 dose escalation cohorts and 2 dose expansion cohorts (350mg BID/ 300mg BID). One DLT (grade 3 ALT increased) occurred at 350 mg BID. The MTD has not been reached. The most common grade 3 adverse events were neutrophils count decreased (20%), ALT increased (6.67%), leucocyte counts decreased (3.33%) and QT internal prolongation (3.33%). Grade 3 adverse events rate were 40% in 350mg BID cohort and 16.67% in 300mg BID cohort. PK analyses indicated TQ-B3101 metabolized into its deacetylated product rapidly, and exposure (Cmax and AUC) of which generally increased in a dose-proportional manner. Tumor response was evaluated in 24 pts with ALK + /ROS1 + /MET amplification. ORR were 62.5% (15/24) in all cohorts, and 87.5% (7/8) in 350mg BID cohort. In 8 pts with brain metastases at baseline, ORR was 62.5% (5/8) . In 22 pts without brain metastases at baseline, the incidence of brain metastasis was 4.55% (1/22). 1 patient with MET amplification is evaluable and the tumor response is PR. Conclusions: TQ-B3101 was well tolerated and showed preliminary antitumor activity in ALK + , ROS1 + and MET amplification pts. Recommended phase II dose (RP2D) might be 300mg BID according longtime safety data. Further anti-tumor research in pts with ROS1 + is under going as multicenter clinical study in China. (NCT03972189). Clinical trial information: NCT03019276.
A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC).
Authors: Diana L. Hanna, Syma Iqbal, Diane Habib, Denice D. Tsao-Wei, Afsaneh Barzi, Jacob Stephen Thomas, Victor Chiu, Imran Siddiqi, Rishi D. Bhavsar, Nicole G. Jensen, Cristina DeLeon, Heinz-Josef Lenz, Parkash S. Gill, Anthony B. El-Khoueiry
Journal: Journal of Clinical Oncology (2020)

4640 Background: EphB4, a receptor kinase expressed in most epithelial tumors, binds EphrinB2 to affect cancer cell growth, apoptosis and angiogenesis. EphB4 overexpression is associated with advanced stage and shorter survival in multiple cancers. sEphB4-HSA, the albumin-bound extracellular fragment of EphB4, is a first-in-class inhibitor which blocks EphB4-EphrinB2 bidirectional signaling and results in downstream suppression of KRAS, PI3K, and promotes recruitment of CD3 and CD8 T cells into the tumor. The RP2D of sEphB4-HSA is 10 mg/Kg IV q week. Here, we report on sEphB4-HSA in combination with standard first-line chemotherapy. Methods: Pts with advanced PC or BC and no prior therapy for metastatic disease were eligible and enrolled into separate cohorts. Pts with PC received gemcitabine 1,000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, 15 of a 28-day cycle. Pts with BC received gemcitabine 1,000 mg/m2 + cisplatin 25 mg/m2 on Days 1, 8 of a 21-day cycle. sEphB4-HSA 10 mg/kg IV was given weekly starting in Cycle 2. Response was assessed every 2 cycles. Primary endpoint was safety and tolerability; secondary endpoints were objective response rate (ORR) by RECIST 1.1, PFS, OS. Expression of EphrinB2 and EphB4 in tumor was examined by IHC and classified as 1+ (weak staining); 2+ (moderate staining); 3+ (strong, uniform staining). Results: A total of 44 pts with advanced PC (n = 21) and BC (n = 23; 70% gallbladder cancer) were enrolled. Median age 66 yrs; ECOG 1 (70%), 52% male. Median number of cycles received were 5 (PC) and 7 (BC). Median PFS was 5.6 mo in PC and 5.8 mo in BC (95% CI: 3.1-8.1 [PC]; 2.7-7.0 [BC]). Median OS was 7.9 mo in PC and 9.1 mo in BC (95% CI: 6.5-15.0 [PC]; 5.4-15.0 [BC]). In response evaluable pts (20 PC, 22 BC), ORR was 40% in PC (95% CI: 21%, 63%) and 23% in BC (95% CI: 9%, 45%). Stable disease was noted in 48% of PC and 61% of BC pts. The most common grade 3 or 4 treatment-related AEs in ≥10% of pts in both cohorts combined were hypertension (n = 16; 36%), neutropenia (n = 15; 34%), anemia (n = 14; 32%), thrombocytopenia (n = 7, 16%), fatigue (n = 7, 16%). In the PC cohort, there was an association between EphB4 expression and objective response (p = 0.009). Conclusions: sEphB4-HSA has a manageable safety profile in combination with chemotherapy in pts with PC and BC. Clinical activity is manifested by a high disease control rate in both cohorts and a promising RR in PC. Additional biomarker analyses will be presented. Future studies combining chemoimmunotherapy with sEphB4-HSA in pancreatic cancer are planned. Clinical trial information: NCT02495896 .
Characteristics of Neuro-Behcet disease: six cases case report and literature review
Authors: Yuhui Chen, Yongjing Cheng, Cibo Huang, Yin Wang, Lianzhe Wu
Journal: BMJ (2015)

Six patients with Neuro-Behcet disease (NBD) were admitted in Beijing Hospital from 2000 to 2014, during the same period 344 NBD cases were reported in the literature. The clinical data of 350 Chinese NBD patients, including the symptoms, signs, laboratory tests, imaging, treatment and prognosis were retrospectively analyzed. The average onset age was 36.7 years old. The average interval time from Behcet disease (BD) to NBD was 5.6 years. NBD often occurred in male, the male/female ratio was 1.94∶1. The most common manifestations were oral ulcer 94.9% (277/292), followed by genital ulcer 69.1% (215/311) and fever 42.1%(131/311). The most common symptoms in neurology were limb weakness (36.9%, 129/350), headache (34.0%, 119/350) and sensory disturbance (21.1%, 74/350), followed by bulbar symptoms (11.4%, 40/350), pyramidal sign was most often (27.1%, 95/350). The central neurology system (CNS) was the major target of NBD, parenchymal CNS was affected most (88.0%, 308/350), non-parenchymal CNS was affected less (5.7%, 20/350), peripheral neurology system (PNS) was rarely affected (6.9%, 24/350). Steroids were the first-line drug for NBD, if it failed, immunosuppressive agents or biologic agents could be used. The most NBD patients had single episodes, 32.0% (49/153) had relapses with remission, 7.7% (27/350) had adverse prognosis. Analysis showed that NBD should be paid more attention.


Key words: 
Behcet syndorme; Diseases attributes